{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.1","value":"115"},{"groupId":"OG001","spread":"41.1","value":"65.8"},{"groupId":"OG002","spread":"32.2","value":"48.2"},{"groupId":"OG003","spread":"402.8","value":"39.2"},{"groupId":"OG004","spread":"77.4","value":"52.1"},{"groupId":"OG005","spread":"37.4","value":"40.7"},{"groupId":"OG006","spread":"71.7","value":"40.8"},{"groupId":"OG007","spread":"0.8","value":"19.9"},{"groupId":"OG008","spread":"74.8","value":"53.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"8"}],"units":"Participants"}],"title":"C1D8: dose escalation phase"},{"categories":[{"measurements":[{"comment":"N/A = not estimable","groupId":"OG000","spread":"NA","value":"133"},{"comment":"N/A = not estimable","groupId":"OG001","spread":"NA","value":"112"},{"groupId":"OG008","spread":"37.1","value":"33.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"23"}],"units":"Participants"}],"title":"C2D1:dose escalation & dose expansion phases"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"252"}],"units":"Participants"}],"description":"CLss/F is the apparent total body clearance of drug from the plasma. There was no PK sampling during C1D1 and C2D1 except for 750 mg dose to compute PK parameter CLss/F.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants receiving 50 mg of LDK378","id":"OG000","title":"LDK378 50 mg"},{"description":"Participants receiving 100 mg of LDK378","id":"OG001","title":"LDK378 100 mg"},{"description":"Participants receiving 200 mg of LDK378","id":"OG002","title":"LDK378 200 mg"},{"description":"Participants receiving 300 mg of LDK378","id":"OG003","title":"LDK378 300 mg"},{"description":"Participants receiving 400 mg of LDK378","id":"OG004","title":"LDK378 400 mg"},{"description":"Participants receiving 500 mg of LDK378","id":"OG005","title":"LDK378 500 mg"},{"description":"Participants receiving 600 mg of LDK378","id":"OG006","title":"LDK378 600 mg"},{"description":"Participants receiving 700 mg of LDK378","id":"OG007","title":"LDK378 700 mg"},{"description":"Participants receiving 750 mg of LDK378.","id":"OG008","title":"LDK378 750 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set (PAS) consisted of all patients (including NSCLC and non-NSCLC) who received at least 1 dose of LDK378 \\& had at least 1 evaluable PK sample","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8 of dose escalation phase, Cycle 2 Day 1 of dose escalation & dose expansion phases","title":"Secondary Pharmacokinetics (PK) Parameter: CLss/F","type":"SECONDARY","unitOfMeasure":"Litres/hour"}